Insider Selling: Clearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $73,280.09 in Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.31, for a total value of $73,280.09. Following the completion of the transaction, the insider owned 81,353 shares of the company’s stock, valued at approximately $269,278.43. This trade represents a 21.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 15th, Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.32, for a total value of $10,567.56.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total transaction of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The shares were purchased at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Price Performance

Shares of Clearmind Medicine stock traded down $0.07 during trading on Thursday, hitting $3.07. 1,278,207 shares of the stock were exchanged, compared to its average volume of 1,141,953. The firm’s 50-day moving average price is $5.75 and its 200 day moving average price is $15.22. The stock has a market cap of $3.13 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a 12-month low of $2.10 and a 12-month high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Monday, June 15th. The company reported ($6.78) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.